GlaxoSmithKline is under pressure from shareholders to rein in pay for its incoming chief executive, Emma Walmsley, according to reports. Walmsley is set to take over from Sir Andrew Witty when he ...
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...
GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
On October 15, 2024, GSK filed two complaints against Moderna in the District Court for the District of Delaware, asserting that Moderna willfully infringes GSK’s mRNA patent portfolio. In Civil ...
GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments.
Other Operating Income------Total Income From Operations: 1,010.77: 814.65: 956.99: EXPENDITURE ...
GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.
Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback